Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 2
2014 2
2015 3
2016 1
2017 2
2018 2
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
The effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data.
Worldwide Antimalarial Resistance Network (WWARN) AL Dose Impact Study Group. Worldwide Antimalarial Resistance Network (WWARN) AL Dose Impact Study Group. Lancet Infect Dis. 2015 Jun;15(6):692-702. doi: 10.1016/S1473-3099(15)70024-1. Epub 2015 Mar 16. Lancet Infect Dis. 2015. PMID: 25788162 Free PMC article. Review.
Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data.
WWARN Artemisinin based Combination Therapy (ACT) Africa Baseline Study Group; Dahal P, d'Alessandro U, Dorsey G, Guerin PJ, Nsanzabana C, Price RN, Sibley CH, Stepniewska K, Talisuna AO. WWARN Artemisinin based Combination Therapy (ACT) Africa Baseline Study Group, et al. BMC Med. 2015 Sep 7;13:212. doi: 10.1186/s12916-015-0445-x. BMC Med. 2015. PMID: 26343145 Free PMC article. Review.
Spread of artemisinin resistance in Plasmodium falciparum malaria.
Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B, Sopha C, Chuor CM, Nguon C, Sovannaroth S, Pukrittayakamee S, Jittamala P, Chotivanich K, Chutasmit K, Suchatsoonthorn C, Runcharoen R, Hien TT, Thuy-Nhien NT, Thanh NV, Phu NH, Htut Y, Han KT, Aye KH, Mokuolu OA, Olaosebikan RR, Folaranmi OO, Mayxay M, Khanthavong M, Hongvanthong B, Newton PN, Onyamboko MA, Fanello CI, Tshefu AK, Mishra N, Valecha N, Phyo AP, Nosten F, Yi P, Tripura R, Borrmann S, Bashraheil M, Peshu J, Faiz MA, Ghose A, Hossain MA, Samad R, Rahman MR, Hasan MM, Islam A, Miotto O, Amato R, MacInnis B, Stalker J, Kwiatkowski DP, Bozdech Z, Jeeyapant A, Cheah PY, Sakulthaew T, Chalk J, Intharabut B, Silamut K, Lee SJ, Vihokhern B, Kunasol C, Imwong M, Tarning J, Taylor WJ, Yeung S, Woodrow CJ, Flegg JA, Das D, Smith J, Venkatesan M, Plowe CV, Stepniewska K, Guerin PJ, Dondorp AM, Day NP, White NJ; Tracking Resistance to Artemisinin Collaboration (TRAC). Ashley EA, et al. Among authors: peshu j. N Engl J Med. 2014 Jul 31;371(5):411-23. doi: 10.1056/NEJMoa1314981. N Engl J Med. 2014. PMID: 25075834 Free PMC article. Clinical Trial.
Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial.
Siika A, McCabe L, Bwakura-Dangarembizi M, Kityo C, Mallewa J, Berkley J, Maitland K, Griffiths A, Baleeta K, Mudzingwa S, Abach J, Nathoo K, Thomason MJ, Prendergast AJ, Walker AS, Gibb DM; REALITY Trial Team. Siika A, et al. Clin Infect Dis. 2018 Mar 4;66(suppl_2):S140-S146. doi: 10.1093/cid/cix1142. Clin Infect Dis. 2018. PMID: 29514235 Free PMC article. Clinical Trial.
Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa.
Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A, Agutu C, Walker S, Pett SL, Bwakura-Dangarembizi M, Lugemwa A, Kaunda S, Karoney M, Musoro G, Kabahenda S, Nathoo K, Maitland K, Griffiths A, Thomason MJ, Kityo C, Mugyenyi P, Prendergast AJ, Walker AS, Gibb DM; REALITY Trial Team. Hakim J, et al. N Engl J Med. 2017 Jul 20;377(3):233-245. doi: 10.1056/NEJMoa1615822. N Engl J Med. 2017. PMID: 28723333 Free PMC article. Clinical Trial.
Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial.
Post FA, Szubert AJ, Prendergast AJ, Johnston V, Lyall H, Fitzgerald F, Musiime V, Musoro G, Chepkorir P, Agutu C, Mallewa J, Rajapakse C, Wilkes H, Hakim J, Mugyenyi P, Walker AS, Gibb DM, Pett SL; Reduction of EArly mortaLITY in HIV-infected adults and children starting antiretroviral therapy (REALITY) Trial Team. Post FA, et al. Clin Infect Dis. 2018 Mar 4;66(suppl_2):S132-S139. doi: 10.1093/cid/cix1141. Clin Infect Dis. 2018. PMID: 29514234 Free PMC article. Clinical Trial.
15 results